The role of Wnt signaling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 11-17

  Hu, Li Wen ^a   Kawamoto, Elisa Mitiko ^a   Brietzke, Elisa ^a   Scavone, Cristóforo ^a   Lafer, Beny ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bipolar disorder; GSK3 ; Inflammation; Neuroplasticity; Wnt

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LITHIUM; MOOD STABILIZER; ROSIGLITAZONE; VALPROIC ACID; WNT PROTEIN;

APOPTOSIS; BIPOLAR DISORDER; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; DEPRESSION; DRUG MECHANISM; EMBRYO PATTERN FORMATION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; MANIA; MEMORY DISORDER; MOLECULAR MECHANICS; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SPATIAL MEMORY;

ANIMALS; ANTIDEPRESSIVE AGENTS; APOPTOSIS; BIPOLAR DISORDER; HUMANS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 78650958063     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.031     Document Type: Review

References (99)

1. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Lameida L., Nardin P., et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychitr Res 2007, 41:523-529.
2. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004, 101:5099-5104.
3. Benes F.M., Matzilevich D., Bruke R.E., Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 2006, 11:241-251.
4. Bielecka A.M., Obuchowicz E. Antiapoptotic actions of lithium and valproate. Pharmacol Rep 2008, 60:771-782.
5. Blumenthal A., Ehlers S., Lauber J., Buer J., Lange C., Goldmann T., et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006, 108:965-973.
6. Brietzke E., Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1355-1361.
7. Brietzke E., Stertz L., Fernandes B.S., Kauer-Sant'anna M., Mascarenhas M., Escosteguy Vargas A., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009, 116:214-217.
8. Brietzke E., Kauer-Sant'anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009, 23:1079-1082.
9. Chen G., Hasanat K.A., Bebchuck B.M., Moore G.J., Glitz D., et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med 1999, 61:599-617.
10. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanism and therapeutic potentials. Ann NY Acad Sci 2005, 1053:195-204.
11. Ciani L., Salinas P.C. Wnts in the nervous vertebrate system: from patterning to neuronal connectivity. Nature Rev Neurosci 2005, 6:351-362.
12. Coryel W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord 2009, 11(suppl 2):77-83.
13. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Gonçalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006, 398:215-219.
14. David M.D., Yeramian A., Duñach M., Llovera M., Cantí C., de Herreros A.G., et al. Signalling by neurotrophins and hepatocyte growth factor regulates axon morphogenesis by differential beta-catenin phosphorylation. J Cell Sci 2008, 121:2718-2730.
15. Davis K.J. Oxidative stress, antioxidant defenses and damages removal, repair and replacement systems. IUBMB Life 2000, 50:279-289.
16. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43:1158-1164.
17. Dechan G., Neumann H. Neutrophins. Adv Exp Med Biol 2002, 513:303-334.
18. Dissanayake S.K., Wade M., Johnson C.E., O'Connell M.P., Leotlela P.D., et al. The Wnt 5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis supressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007, 282:17259-17271.
19. Drevets W.C., Price J.L., Simpson J.R., Todd R.D., Reich T., et al. Subgenual prefrontaç cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
20. Drexhage R.C., Knijjf E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., et al. The mononuclear phagocytes system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010, 10:59-76.
21. Du S.J., Purcell S.M., Christian J.L., McGrew L.L., Moon R.T. Identification of distinct classes and functional domains of Wnts through expression of wild-type and chimeric proteins in Xenopus embryos. Mol Cell Biol 1995, 15:2625-2634.
22. Filomeni G., Ciriolo M.R. Redox control of apoptosis: and update. Antioxid Redox Signal 2006, 8:2187-2192.
23. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of aging. Nature 2000, 408:239-247.
24. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs:are the answers in sight?. Nat Rev Genet 2008, 9:102-114.
25. Gazalle F.K., Kapczinski F. Mogens Schou and use of lithium in psychiatry. Rev Bras Psiq 2006, 28:82-83.
26. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70:1078-1090.
27. Gómez-Sintes R., Lucas J.J. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest 2010, 120:2432-2445.
28. Goto Y., Yang C.R., Otani S. Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol Psychiatry 2010, 67:199-207.
29. Gould T.D., Einat H., Bhat R., Manji Hk. AR-A014418, a selective inhibitor produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004, 7:387-390.
30. Gould T.D., Cheng G., Manji H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004, 29:32-38.
31. Grassi-Oliveira R., Brietzke E., Pezzi J.C., Lopes R.P., Teixeira A.L., Bauer M.E. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin Neurosci 2009, 63:202-208.
32. Hooper C., Markevich V., Plattner F., Killick R., Schofield E., Engel T., et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 2007, 25:81-86.
33. Inkster B., Nichols T.E., Saemann P.G., Auer D.P., Holsboer F., et al. Association of GSK3beta polymorphyisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 2009, 66:721-728.
34. Jin T., George Fantus I., Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal 2008, 20:1697-1704.
35. Kaidanovich-Beilin O., Milman A., Weizman A., Pick C.G., Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004, 55:781-784.
36. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008, 8:1101-1113.
37. Karege F., Perroud N., Burkhardt S., Schwald M., Ballmann E., et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007, 61:240-245.
38. Kato T., Kato n. Mitochondrial dysfunction in bipolar disorder. Bipolar Disorder 2000, 2:180-190.
39. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007, 104:91-95.
40. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc NY Acad Sci USA 1996, 93:8455-8459.
41. Knijff E.M., Breunis M.N., Kupka R.W., de Wit H.J., Ruwhof C. An imbalance in the production of IL-1 beta and IL-6 by monocytes of bipolar patients: restoration of lithium treatment. Bipolar Disord 2007, 9:743-753.
42. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3beta immunoreactivity in posmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 2000, 157:831-833.
43. Lesort M., Greendorfer A., Stockmeier C., Johnson G.V.W., Jope R.S. Glycogen synthase kinase-3β, β-catenin and tau in postmortem bipolar brain. J Neural Transm 1999, 106:1217-1222.
44. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3 beta by serotonergic activity in mouse brain. Neuropsychopharmacoloy 2004, 29:137-144.
45. Li X., Rosborough K.M., Friedman A.B., Zhu V.V., Roth K.A. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. J Int Neuropsychopharmacol 2007, 10:7-19.
46. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
47. Machado-Vieira R., Dietrich M.O., Leke R., Cereser V.H., Zanatto V., Kapczinski F., et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007, 61:142-144.
48. McAfoose J., Koerner H., Baune B.T. The effects of TNF deficiency on age-related cognitive performance. Psychoneuroendocrinology 2009, 34:615-619.
49. Malhi G., Adams D., Cahil C.M., Dodd S., Berk M. The management of individuals with bipolar disorder: a review of the evidences. Drugs 2009, 69:2063-2101.
50. Manji H.K., Bebchuk J.M., Moore G.J., Glitz D., Hasanat K.A., Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psych 1999, 60:27-39.
51. Manji H.K., Moore G.J., Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?. Biol Psychiatry 1999, 46:929-940.
52. Marques A.H., Cizza G., Sternberg E. Brain-immune interactions and implications in psychiatric disorders. Rev Bras Psiquiatr 2007, 29:S27-S32.
53. Mensulam M.M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999, 24:521-529.
54. Mhyre R.T., Loy R., Tariot N.M., Profenno L.A., Maguire-Zeiss K.A., Zhang D. Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging 2008, 29:1631-1634.
55. Mikels A.J., Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006, 25:7461-7468.
56. Monteleone P., Serritella C., Martiadis V., Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and euthymic patients with bipolar I and II disorders. Bipolar Disord 2008, 10:95-100.
57. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009, 2:95-109.
58. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. Wnt and β-catenin signaling: diseases and therapies. Nature Rev 2004, 5:691-701.
59. Novina C.D., Sharp P.A. The RNAi revolution. Nature 2004, 430:161-164.
60. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006, 90:263-267.
61. Ongur D., Drevts W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. PNAS 1998, 95:13290-13295.
62. Ortiz-Domínguez A., Hernández M.E., Berlanga C., Gutiérrez-Mora D., Moreno J., Heinze G., et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disorder 2007, 9:596-602.
63. Palomino A., Vallejo-Illarramendi A., González-Pinto A., Aldama A., González-Gómez C., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006, 86:321-322.
64. Pandey G.N., Ren X., Rizavi H.S., Dwivedi Y. Glycogen synthase kinse 3-beta in the platelets of patients with mood disorders: effects of treatment. J Psychiatr Res 2010, 44:143-148.
65. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 2000, 287:1606-1609.
66. Pereira C.P., Bachli E.B., Schoedon G. The wnt pathway: a macrophage effector molecule that triggers inflammation. Curr Atheroscler Rep 2009, 11:236-242.
67. Polter A., Beurel E., Yang S., Garner R., Song L., et al. Deficiency in the inhibitory serine phosphorylation in glycogen synthase kinase 3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010, 35:1761-1774.
68. Post R.M. Kindling and sensitization as models for affective recurrence, ciclicity and tolerance phenomena. Neurosci Biobehav Rev 2007, 31:858-873.
69. Prickaerts J., Moecharts D., Cryns K., Lenaerts I., van Craenendock H., et al. Transgenic mice overexpression glycogen synthase kinase-3beta: a putative model of hyperactive and mania. J Neurosci 2006, 26:9022-9029.
70. Raison C.L., Lin J.M., Reeves W.C. Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun 2009, 23:327-337.
71. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
72. Reishl J., Schwenke S., Beekman J.M., Mrowietz U., Stürzebecher S., Heubach J.F. Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 2007, 127:163-169.
73. Rowe M.K., Wiest C., Chuang D.M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007, 31:920-931.
74. Saus E., Soria V., Escaramís G., Crespo J.M., Valero J., et al. A haplotype of glycogen synthase kinase-3beta is associated with early onset of unipolar depression. Genes Brain Behav 2010, (Epub ahead of print).
75. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
76. Schou M. Forty years of lithium of lithium treatment. Arch Gen Psychiatry 1997, 54:9-13.
77. Sen M., Lauterbach K., El-Gabalawy H., Firestein G.S., Corr M., Carson D.A. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A 2000, 97:2791-2796.
78. Shimogori T., VanSant J., Paik E., Grove E.A. Members of Wnt, Fz and Frp gene families expressed in postnatal mouse cerebral cortex. J Comp Neurol 2004, 473:496-510.
79. Shimsoni J.A., Dalton E.C., Jenkins A., Eyal S., Ewan K., et al. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol Pharmacol 2007, 71:884-892.
80. Shoval G., Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005, 15:319-329.
81. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991, 91:31S-38S.
82. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leão P., et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008, 152:656-669.
83. Soares J.C., Gershon S. The lithium ion: a foundation for psychopharmacological specificity. Neuropsychopharmacology 1998, 19:167-182.
84. Soreca I., Frank E., Kupfer D.J. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis?. Depress Anxiety 2009, 26:73-82.
85. Takeichi M., Abe K. Synaptic contact dynamics controlled by cadherin and catenins. Trends Cell Biol 2005, 15:216-221.
86. Tissir F., Goffinet A.M. Expression of planar cell polarity genes during development of mouse CNS. Eur J Neurosci 2006, 23:597-607.
87. Toledo E.M., Inestrosa N.C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 2010, 15:272-285.
88. Tolwinski N.S., Wieschaus E. Rethinking WNT signaling. Trends Genet 2004, 20:1.
89. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Stertz L, Goi J, Chiarani F et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009;452:111-3. 77-81.
90. Vasconcellos A.P., Tabajara A.S., Ferrari C., Rocha E., Dalmaz C. Effect of chronic stress on spatial memory in rats is attenuated by lithium treatment. Physiol Behav 2003, 79:143-149.
91. Veeman M.T., Slusarski D.C., Kaykas A., Louie S.H., Moon R.T. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Currrent Biol 2003, 13:680-685.
92. Wallingford J.B., Vogeli K.M., Harland R.M. Regulation of convergent extension in Xenopus by Wnt5a and Frizzled-8 is independent of the canonical Wnt pathway. Int J Dev Biol 2001, 45:225-227.
93. Wang H., Zhang R., Wen S., McCafferty D.-M., Beck P.L., MacNuaghton W.K. Nitric oxide increases Wnt-induced secreted protein-1 (WSIP-1/CCN4) expression and function in colitis. J Mol Med 2009, 87:435-445.
94. Wodarz A., Nusse R. Mechanisms of Wnt signaling in development. Ann Rev Cell Dev Biol 1998, 14:59-88.
95. Wood G.E., Young L.T., Reagan L.P., Chen B., McEwen B.S. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci U S A 2004, 101:3973-3978.
96. Woodgett J.R. Judging a protein by more than its name: gsk-3. Sci STKE 2001, 100:re12.
97. Zandi P.P., Belmonte P.L., Willour V.L., Goes F.S., Badner J.A., Simpson S.G., et al. Association study of Wnt signaling pathway genes in bipolar disorder. Arch Gen Psych 2008, 65:785-793.
98. Zanetti M.V., Jackowski M.P., Versace A., Almeida J.R., Hassel S., Duran F.L., et al. State-dependent microstructural white matter changes in bipolar I depression. Eur Arch Psychiatry Clin Neurosci 2009, 259:316-328.
99. Zhou L., Yuan P., Wang Y., Hunsberger J.G., Elkahloun A., Wei Y., et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009, 34:1395-1405.